Detectable size of melanoma metastases to brain on PET/CT
Annals of Nuclear Medicine, ISSN: 1864-6433, Vol: 34, Issue: 8, Page: 545-548
2020
- 2Citations
- 11Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations2
- Citation Indexes2
- Captures11
- Readers11
- 11
Article Description
Objective: We aimed to determine at what size melanoma metastases become detectable by PET/CT. Methods: We reviewed a total of 293 whole-body PET/CT studies performed on 212 patients for staging of melanoma where there was an MRI within a month of the PET/CT. MR and PET/CT were reviewed independently by separate readers. Results: PET/CT revealed an overall incidental true-positive rate of 1% on a per-patient basis, consistent with other studies, with ‘hot’ lesions (more avid than brain parenchyma) visible at smaller sizes than ‘cold’ lesions. Conclusions: PET/CT can detect metastatic melanoma lesions over about 2 cm in size, with hot lesions generally visible at smaller sizes.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85085317952&origin=inward; http://dx.doi.org/10.1007/s12149-020-01481-8; http://www.ncbi.nlm.nih.gov/pubmed/32451886; https://link.springer.com/10.1007/s12149-020-01481-8; https://dx.doi.org/10.1007/s12149-020-01481-8; https://link.springer.com/article/10.1007/s12149-020-01481-8
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know